Which has better earnings and valuation, XNCR or SYRE?

Xencor has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $104.97M 17.59 -$91.92M -$2.17 N/A Spyre Therapeutics $890K 9,208.01 -$155.20M -$1.95 N/A

Does the media prefer XNCR or SYRE?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Xencor. MarketBeat recorded 15 mentions for Spyre Therapeutics and 10 mentions for Xencor. Xencor's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.43 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, XNCR or ALKS?

Alkermes has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $104.97M 17.59 -$91.92M -$2.17 N/A Alkermes $1.48B 4.75 $241.66M $0.38 109.87

Is XNCR or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Xencor's net margin of -155.59%. Alkermes' return on equity of 4.15% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to XNCR or ALKS?

In the previous week, Xencor had 4 more articles in the media than Alkermes. MarketBeat recorded 10 mentions for Xencor and 6 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Xencor's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IMVT or XNCR?

Xencor has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Xencor $104.97M 17.59 -$91.92M -$2.17 N/A

Is IMVT or XNCR more profitable?

Immunovant has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Xencor -155.59% -28.66% -20.38%

Does the media prefer IMVT or XNCR?

In the previous week, Xencor had 2 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Xencor and 8 mentions for Immunovant. Xencor's average media sentiment score of 0.58 beat Immunovant's score of 0.00 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Xencor 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or XNCR?

In the previous week, Xencor had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 10 mentions for Xencor and 4 mentions for Rhythm Pharmaceuticals. Xencor's average media sentiment score of 0.58 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IOVA or XNCR?

In the previous week, Iovance Biotherapeutics had 39 more articles in the media than Xencor. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 10 mentions for Xencor. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Xencor's score of 0.58 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 11 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xencor (XNCR) Competitors

$24.84 +0.07 (+0.28%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$25.05 +0.21 (+0.85%)

As of 10/2/2026 07:41 PM Eastern

Compare

XNCR vs. SYRE, ALKS, IMVT, RYTM, and IOVA

Should you buy Xencor stock or one of its competitors? Xencor's main competitors and comparable companies include Spyre Therapeutics (SYRE), Alkermes (ALKS), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xencor compare to Spyre Therapeutics?

Xencor (NASDAQ:XNCR) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Xencor currently has a consensus target price of $34.00, suggesting a potential upside of 36.88%. Spyre Therapeutics has a consensus target price of $109.71, suggesting a potential upside of 17.73%. Given Xencor's higher possible upside, equities research analysts clearly believe Xencor is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Xencor has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, indicating that its share price is 210% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Xencor. MarketBeat recorded 15 mentions for Spyre Therapeutics and 10 mentions for Xencor. Xencor's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.43 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xencor has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$104.97M	17.59	-$91.92M	-$2.17	N/A
Spyre Therapeutics	$890K	9,208.01	-$155.20M	-$1.95	N/A

80.4% of Spyre Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spyre Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Summary

Spyre Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Xencor compare to Alkermes?

Xencor (NASDAQ:XNCR) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Alkermes has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$104.97M	17.59	-$91.92M	-$2.17	N/A
Alkermes	$1.48B	4.75	$241.66M	$0.38	109.87

Xencor currently has a consensus target price of $34.00, indicating a potential upside of 36.88%. Alkermes has a consensus target price of $54.47, indicating a potential upside of 30.47%. Given Xencor's higher probable upside, equities analysts plainly believe Xencor is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Alkermes has a net margin of 3.96% compared to Xencor's net margin of -155.59%. Alkermes' return on equity of 4.15% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
Alkermes	3.96%	4.15%	2.19%

95.2% of Alkermes shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xencor had 4 more articles in the media than Alkermes. MarketBeat recorded 10 mentions for Xencor and 6 mentions for Alkermes. Alkermes' average media sentiment score of 0.82 beat Xencor's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Summary

Alkermes beats Xencor on 12 of the 17 factors compared between the two stocks.

How does Xencor compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Immunovant has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Xencor	-155.59%	-28.66%	-20.38%

In the previous week, Xencor had 2 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Xencor and 8 mentions for Immunovant. Xencor's average media sentiment score of 0.58 beat Immunovant's score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xencor	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Xencor	$104.97M	17.59	-$91.92M	-$2.17	N/A

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 30.87%. Xencor has a consensus price target of $34.00, indicating a potential upside of 36.88%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Immunovant has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Xencor has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Xencor beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Xencor compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Xencor has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$239.92M	26.52	-$196.54M	-$3.11	N/A
Xencor	$104.97M	17.59	-$91.92M	-$2.17	N/A

Rhythm Pharmaceuticals presently has a consensus target price of $140.67, indicating a potential upside of 51.53%. Xencor has a consensus target price of $34.00, indicating a potential upside of 36.88%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Rhythm Pharmaceuticals has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Xencor has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Xencor	-155.59%	-28.66%	-20.38%

In the previous week, Xencor had 6 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 10 mentions for Xencor and 4 mentions for Rhythm Pharmaceuticals. Xencor's average media sentiment score of 0.58 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xencor	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xencor beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Xencor compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Iovance Biotherapeutics has a net margin of -89.11% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Xencor	-155.59%	-28.66%	-20.38%

In the previous week, Iovance Biotherapeutics had 39 more articles in the media than Xencor. MarketBeat recorded 49 mentions for Iovance Biotherapeutics and 10 mentions for Xencor. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Xencor's score of 0.58 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	11 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	19.82	-$390.98M	-$0.73	N/A
Xencor	$104.97M	17.59	-$91.92M	-$2.17	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Iovance Biotherapeutics currently has a consensus price target of $12.40, indicating a potential downside of 12.80%. Xencor has a consensus price target of $34.00, indicating a potential upside of 36.88%. Given Xencor's higher possible upside, analysts clearly believe Xencor is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Iovance Biotherapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Xencor has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Xencor on 10 of the 17 factors compared between the two stocks.

Get Xencor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XNCR vs. The Competition

Export

Metric	Xencor	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-11.45	13.06	274.33	26.04
Price / Sales	17.59	1,290.02	616.11	85.50
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	2.79	16.63	10.93	6.31
Net Income	-$91.92M	-$22.71M	$3.51B	$362.16M
7 Day Performance	4.37%	-2.98%	-2.02%	-1.67%
1 Month Performance	-6.69%	-10.59%	-6.17%	-4.51%
1 Year Performance	111.05%	19.46%	7.45%	2.03%

Xencor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XNCR Xencor	2.0091 of 5 stars	$24.84 +0.3%	$34.00 +36.9%	+110.2%	$1.84B	$104.97M	N/A	260	Analyst Forecast Gap Up
SYRE Spyre Therapeutics	2.0803 of 5 stars	$83.91 -2.2%	$109.69 +30.7%	+483.2%	$7.37B	$890K	N/A	112	Trending News Analyst Forecast Insider Trade
ALKS Alkermes	2.8189 of 5 stars	$40.64 +1.2%	$54.47 +34.0%	+33.6%	$6.80B	$1.48B	106.67	2,050
IMVT Immunovant	2.0669 of 5 stars	$32.58 -2.7%	$44.00 +35.0%	+101.0%	$6.73B	N/A	N/A	315
RYTM Rhythm Pharmaceuticals	2.7009 of 5 stars	$96.45 -2.1%	$140.67 +45.9%	-4.5%	$6.60B	$189.76M	N/A	414

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XNCR) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xencor (XNCR) Competitors

XNCR vs. SYRE, ALKS, IMVT, RYTM, and IOVA

How does Xencor compare to Spyre Therapeutics?

Summary

How does Xencor compare to Alkermes?

Summary

How does Xencor compare to Immunovant?

Summary

How does Xencor compare to Rhythm Pharmaceuticals?

Summary

How does Xencor compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xencor (XNCR) Competitors

XNCR vs. SYRE, ALKS, IMVT, RYTM, and IOVA

How does Xencor compare to Spyre Therapeutics?

Do analysts rate XNCR or SYRE?

Which has more volatility & risk, XNCR or SYRE?

Does the media prefer XNCR or SYRE?

Which has better earnings and valuation, XNCR or SYRE?

Do insiders & institutionals have more ownership in XNCR or SYRE?

Is XNCR or SYRE more profitable?

Summary

How does Xencor compare to Alkermes?

Which has stronger valuation and earnings, XNCR or ALKS?

Do analysts rate XNCR or ALKS?

Is XNCR or ALKS more profitable?

Do insiders and institutionals believe in XNCR or ALKS?

Does the media refer more to XNCR or ALKS?

Which has more volatility and risk, XNCR or ALKS?

Summary

How does Xencor compare to Immunovant?

Is IMVT or XNCR more profitable?

Does the media prefer IMVT or XNCR?

Which has stronger valuation and earnings, IMVT or XNCR?

Do analysts rate IMVT or XNCR?

Which has more volatility & risk, IMVT or XNCR?

Do insiders & institutionals hold more shares of IMVT or XNCR?

Summary

How does Xencor compare to Rhythm Pharmaceuticals?

Which has better earnings & valuation, RYTM or XNCR?

Do analysts rate RYTM or XNCR?

Which has more volatility and risk, RYTM or XNCR?

Is RYTM or XNCR more profitable?

Does the media prefer RYTM or XNCR?

Summary

How does Xencor compare to Iovance Biotherapeutics?

Is IOVA or XNCR more profitable?

Does the media prefer IOVA or XNCR?

Which has preferable valuation and earnings, IOVA or XNCR?

Do institutionals and insiders have more ownership in IOVA or XNCR?

Do analysts prefer IOVA or XNCR?

Which has more risk & volatility, IOVA or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XNCR vs. The Competition

Xencor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools